To carry out the study, retrospective clinical data was collected by researchers from clinicians and caretakers of 10 children with drug-resistant epilepsy. The researchers ensured that the 10 patients recruited for the research had not responded to any CBD products. The children recruited were of the average age of six but ranged between 1 to 13 years. These kids had a range of epilepsies and various kinds of co-existing issues like learning abilities, global developmental delay, and infantile spasms.